Skip to main content

Table 2 Adverse events

From: Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting

Toxicity

T + C (n = 50)

T (n = 67)

Any

≥3

Any

≥3

Skin rash

32(64.00%)

2(4.00%)

47(70.15%)

2(2.99%)

Elevated AST / ALT

31(62.00%)

6(12.00%)

34(50.74%)

7(10.45%)

Diarrhoea

19(38.00%)

1(2.00%)

24(35.82%)

1(1.49%)

Leukopenia / Neutropenia

22(44.00%)

7(14.00%)

5(7.46%)

0(0.00%)

Anaemia

19(38.00%)

5(10.00%)

6(8.96%)

0(0.00%)

Thrombocytopenia

17(34.00%)

6(12.00%)

6(8.96%)

0(0.00%)

Nausea / Vomiting

14(28.00%)

2(4.00%)

7(10.45%)

0(0.00%)

Fatigue

16(32.00%)

2(4.00%)

5(7.46%)

0(0.00%)

Anorexia

15(30.00%)

2(4.00%)

710.45%)

1(1.49%)

Mucositis

12(24.00%)

1(1.23%)

9(13.43%)

1(1.49%)

Constipation

10(20.00%)

0(0.00%)

7(10.45%)

0(0.00%)